- Conditions
- Transgenderism, Kidney Diseases, Kidney Injury
- Interventions
- p-aminohippurate clearance study, Iohexol infusion
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 17 Years to 30 Years
- Enrollment
- 22 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 880
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Participants
- Interventions
- Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Postmenopause, Hypertension, Pre-Hypertension
- Interventions
- Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
- Conditions
- Temporomandibular Joint Disorders
- Interventions
- Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
- Behavioral · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Endometriosis
- Interventions
- elagolix, estradiol/norethindrone acetate (E2/NETA)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Orthostatic Intolerance
- Interventions
- Ganirelix acetate, 17β-Oestradiol, Progesterone
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Prostatic Neoplasms
- Interventions
- Doxorubicin, Ketoconazole, Docetaxel, Estramustine, Degarelix
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Everolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more
- Conditions
- Endometrial Cancer
- Interventions
- conjugated estrogens
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 2,108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 99 more
- Conditions
- HIV Infections
- Interventions
- Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 16 Years to 35 Years · Female only
- Enrollment
- 6,360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- NSCLC
- Interventions
- CT-2103/carboplatin, paclitaxel/carboplatin
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 44
- States / cities
- Scottsdale, Arizona • Fort Smith, Arkansas • Burbank, California + 37 more
- Conditions
- Turner's Syndrome
- Interventions
- Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 138 Months to 13 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan
- Conditions
- Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
- Interventions
- Palbociclib, Bosutinib, Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Vasomotor Symptoms, Endometrial Safety
- Interventions
- Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 70 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 2 more
- Conditions
- Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception
- Interventions
- Non-hormonal period, Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
- Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Menopause
- Interventions
- Estradiol , estriol , progesterone, estradiol, progesterone, estriol, progesterone, equine estrogens m-progesteroneacetate
- Drug
- Lead sponsor
- Jeanne Drisko, MD, CNS, FACN
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Endometrial Dysfunction
- Interventions
- Estradiol Valerate, Progesterone in Oil, Leuprolide
- Other
- Lead sponsor
- Reproductive Medicine Associates of New Jersey
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Basking Ridge, New Jersey
- Conditions
- Amenorrhea, Bone Loss
- Interventions
- Estrogen
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 21 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Contraception
- Interventions
- Relugolix Combination Therapy
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 109
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
- Conditions
- HR+/HER2-negative Breast Cancer
- Interventions
- TOS-358, Fulvestrant, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- Totus Medicines
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more
- Conditions
- Breast Cancer
- Interventions
- Vagifem
- Behavioral
- Lead sponsor
- Susan Tannenbaum
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Healthy Subjects
- Interventions
- lemborexant, Loestrin, famotidine, fluconazole
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Menopause
- Interventions
- esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more